Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease

Phase

Condition

Neuroblastoma

Treatment

N/A

Clinical Study ID

NCT05272371

ChIm-NB-PL

Ages 1-18
All Genders

Study Summary

Safety evaluation and initial efficacy evaluation will be conducted in a group of patients as a non-commercial, open-label clinical trial of dinutuximab beta (Qarziba) phase IIa.

The investigational medicinal product will be dinutuximab beta (anti-GD2 antibodies against GD2 disialoganglioside on NBL cells) at a dose of 10 mg / m2 / day by continuous infusion for 5 days in combination with irinotecan / temozolomide, topotecan / temozolomide or N5 / N6 chemotherapy GPOH protocol.

The study group will be patients with recurrent / progression of NBL or disease resistant to first-line treatment, for whom there are currently no standards of management, and the treatment methods used so far do not give a chance to achieve a permanent remission of the disease. After diagnosis of relapse / progression or resistance to treatment, it is permissible to administer 2 cycles of standard chemotherapy prior to enrollment in the study.

The study plans to recruit 20 patients who will receive 5-7 cycles of DB with chemotherapy. The choice of an appropriate chemotherapy regimen will depend on the patient's prior treatment and tolerance.

The safety assessment will be conducted based on the registration of the types and frequency of adverse reactions identified on the basis of the registration of clinical parameters, symptoms and / or diseases reported by the patient or identified during the intervention and / or follow-up visits, abnormal laboratory and / or imaging test results.

The initial assessment of the effectiveness will consist in comparing the percentage of objective responses obtained and the annual EFS and PFS (imaging tests, including scintigraphy, bone marrow examination and tumor markers). The study also included an exploratory evaluation of the usefulness of immunological, genetic and other studies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Diagnosis of NBL according to international criteria (International Neuroblastoma RiskGroup, INRG).
Patients 1-18 years of age with HR-NBL with primary refractory disease, diseaseprogression or recurrence.
Adequate function of vital organs (if abnormal, dysfunction below grade 4 according tothe CTC AE WHO classification, except for disorders defined in the exclusioncriteria).
Life expectancy ≥6 months.
Obtaining the informed written consent of the patient and/or statutory representativefor the treatment.
Female patients of childbearing potential must consent to the use of effectivecontraception; Breastfeeding patients must consent to the termination ofbreastfeeding.
Patients who have previously received immunotherapy with DB or other anti-GD2 specificantibodies may be eligible for this study.

Exclusion

Exclusion Criteria:

Patients with toxicities of ≥3 CTCAE WHO grade, except hearing impairment,hematological disorders, liver and kidney disorders.
Patients with neurological toxicities of ≥2 CTCAE WHO grade.
Active life-threatening infection until stabilization of the patient's condition.
Pregnancy and / or lactation.
Sexually active patients who refuse to use an effective method of contraception.
Current treatment with experimental drugs or use of such treatment within 2 weeksbefore signing the informed consent to participate in the study.
Radiotherapy within 3 weeks prior to the start of the study.
Participation in another clinical trial within 6 months before signing the informedconsent to participate in the trial (not applicable to clinical trials in 1st line oftreatment in HR-NBL).
Lack of informed written consent to treatment.

Study Design

December 01, 2021

December 31, 2026

Study Description

Neuroblastoma (NBL) accounts for 8-10% of all childhood malignancies. It is the most common solid tumor outside the central nervous system in people <18 years of age. It occurs in 6-11 / 1 million children annually. In Poland, NBL is diagnosed annually in 60-70 patients, in 1/3 high-risk disease (HR). In 90% of children, NBL is diagnosed before the age of 5. The diagnosis is made on the basis of the histopathological assessment of the tumor tissue or the presence of NBL cells in the bone marrow together with elevated levels of catecholamines or their metabolites in the urine. The prognostic factors include the patient's age at diagnosis, stage of disease, tumor histopathology, DNA ploidy, MYCN gene status, chromosomal changes, and initial response to therapy. Due to the different course of the disease, the therapeutic decision is made after determining the risk group based on international criteria (International Neuroblastoma Risk Group Stage System, INRGSS and International Neuroblastoma Staging System, INSS). In the lowest-risk group, management is limited to observation or surgery, and in the intermediate-risk group, only standard low- and intermediate-intensity chemotherapy or combined with radiation therapy and surgery is performed. In contrast, HR-NBL uses intensive combination therapy, including standard induction chemotherapy, surgery, high-dose chemotherapy (HD-CHT) and autologous hematopoietic stem cell transplantation (auto-HSCT), radiotherapy and maintenance therapy with 13-cis retinoic acid and targeted immunotherapy with anti-GD2 antibodies. Treatment outcomes in NBL vary from spontaneous tumor regression in some infants to an OS rate of <50% despite intensive combination therapy in the HR-NBL group.

Connect with a study center

University Children Hospital
Krakow, Malopolska 30-663
Poland
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.